首页> 外文期刊>Journal of Translational Medicine >Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results

【24h】

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results

机译：口服选择性BRAF抑制剂LGX818与口服MEK1 / 2抑制剂MEK162联合进行的Ib / II期，开放标签，剂量递增研究，用于BRAF V600依赖性晚期实体瘤患者：初步结果

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of Translational Medicine》 |2014年第1期|共页
作者
Richard Kefford; Ryan J Sullivan; Wilson H Miller Jr; Elena M Elez; Daniel Tan; Kevin B Kim; Georgina V Long; Keith T Flaherty; David Tai; Simone Stutvoet; Heiko Maacke; Matt Whiley; Laure Moutouh-de Parseval; Josep Tabernero;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类心脏、血管（循环系）疾病;
关键词

相似文献

外文文献
专利

1. A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors [J] . Bedard Philippe L., Tabernero Josep, Janku Filip, Clinical cancer research: an official journal of the American Association for Cancer Research . 2015,第4期

机译：口服Pan-PI3K抑制剂Buparlisib（BKM120）与口服MEK1 / 2抑制剂曲美替尼（GSK1120212）结合用于某些晚期实体瘤患者的Ib期剂量递增研究
2. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors [J] . Tolcher Anthony W., Kurzrock Razelle, Valero Vincente, Cancer chemotherapy and pharmacology. . 2020,第4期

机译：I期升级试验口腔AKT抑制剂Uprosertib与患有实体肿瘤患者的口腔Mek1 / Mek2抑制剂靶毒素组合
3. A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations [J] . Voss Martin H., Hierro Cinta, Heist Rebecca S., Clinical cancer research: an official journal of the American Association for Cancer Research . 2019,第9期

机译：患有FGFR基因改变的晚期实体肿瘤患者口腔选择性FGFR抑制剂Debio 1347的I阶段I，开放标签，多中心，剂量升级研究
4. PHASE II OPEN-LABEL STUDY OF SINGLE-AGENT HYDROXYUREA FOR TREATMENT OF ADVANCED CUTANEOUS MAST CELL TUMORS IN DOGS [C] . Ken Rassnick, Renee Al-Sarraf, Dennis Bailey, Annual Conference of the Veterinary Cancer Society . 2009

机译：单药羟基脲的第II期开放标签研究，用于治疗犬晚皮腰肿瘤瘤
5. Phase Ib/II open-label dose-escalation study of LGX818 an oral selective BRAF inhibitor in combination with MEK162 an oral MEK1/2 inhibitor in patients with BRAF V600-dependent advanced solid tumors: preliminary results [O] . Richard Kefford, Ryan J Sullivan, Wilson H Miller Jr, 2014

机译：口服选择性BRAF抑制剂LGX818与口服MEK1 / 2抑制剂MEK162联合进行的BRAF V600依赖性晚期实体瘤患者的Ib / II期开放标签剂量递增研究：初步结果
6. Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results [O] . Richard Kefford, Ryan J Sullivan, Wilson H Miller, 2014

机译：口服选择性BRAF抑制剂LGX818与口服MEK1 / 2抑制剂MEK162联合进行的Ib / II期，开放标签，剂量递增研究，用于BRAF V600依赖性晚期实体瘤患者：初步结果

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号